Its securities will remain halted until the start of normal trading on Monday, May 10, 2021, or until an announcement is released to the market.
() (LON: MXC) () () has been granted a trading halt by the ASX ahead of the release of a company announcement on further findings on ArtemiC.
The company’s securities will remain halted until the start of normal trading on Monday, May 10, 2021, or until an announcement is released to the market.
Recently, the company received a A$1 million wholesale order from Swiss firm for MGC’s proprietary ArtemiC Rescue supplement, which is being used by COVID-19 patients to support recovery.
It is the second wholesale purchase order received under an agreement with the Swiss company.
Under the terms of the three-year master agreement, SPC is required to order a minimum quantity of 40,000 wholesale units per quarter, which has already been achieved for the second quarter of 2021 following receipt of this order.
MGC Pharma has existing food supplement manufacturing capacity in Slovenia to produce this and any subsequent orders it may receive from SPC this quarter.
Read More: MGC Pharmaceuticals Ltd in trading halt pending announcement by the company on